Interleukin-1 receptor complex (IL-1R complex) (IL-1R complex)

The Interleukin-1 (IL-1) signaling complex is a pivotal heteromeric assembly essential for initiating the innate immune response and driving systemic inflammation (Sims & Smith, 2014, Nature Reviews Immunology). The complex is primarily composed of the Interleukin-1 receptor type 1 (IL-1R1) and the Interleukin-1 receptor accessory protein (IL-1RAcP), which dimerize upon the binding of the proinflammatory cytokines IL-1 alpha or IL-1 beta (Fields et al., 2019, Nature Communications). This dimerization recruits adapter proteins like MyD88, leading to the activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, which induce the expression of numerous inflammatory genes (Weber et al., 2010, Science Signaling). Overactivation or dysregulation of this signaling complex is a hallmark of autoinflammatory diseases, such as Cryopyrin-Associated Periodic Syndromes (CAPS), and contributes to the progression of chronic conditions like rheumatoid arthritis and cardiovascular disease (Dinarello, 2011, Blood). Pharmacological intervention typically involves blocking the receptor with antagonists like Anakinra, neutralizing the ligands with monoclonal antibodies like Canakinumab, or using decoy receptors like Rilonacept to prevent complex formation (Abbate et al., 2020, Journal of the American College of Cardiology). These therapies are highly effective in reducing systemic inflammation but carry risks of immunosuppression and increased susceptibility to infections (FDA Label: Kineret, Ilaris).

Other names

IL-1 signaling complexIL-1R1/IL-1RAcP complexInterleukin-1 receptor type 1 complexIL-1 receptor assemblyIL-1R/IL-1RAcP heterotrimer

Competitive inhibition of IL-1 binding to the IL-1R1 subunit, neutralization of circulating IL-1 alpha or IL-1 beta ligands, or decoy receptor-mediated sequestration of ligands to prevent the assembly of the active signaling complex and subsequent downstream kinase activation.